{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:04:46Z","timestamp":1790251486907,"version":"4.1.0"},"reference-count":149,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Numerous therapeutic agents have been demonstrated to initiate antitumor immune responses, thereby driving significant progress in cancer immunotherapy. However, clinical translation is severely limited by persistent challenges, including systemic toxicity, the immunosuppressive tumor microenvironment (TME), and low nanoparticle delivery efficiency. Tumor-activated prodrug nanoparticles (PDNPs) integrate prodrug chemistry with nanoscale delivery, enabling localized drug activation in response to tumor microenvironmental cues or exogenous stimuli. Therapeutic specificity is improved and off-target toxicity is mitigated by this strategy, providing a promising platform for safe and effective drug delivery. Consequently, these systems have attracted extensive research attention. In this review, the design strategies, release mechanisms, and immunotherapeutic applications of TME-responsive and exogenous stimulus-responsive PDNPs are systematically detailed, together with active-targeting and hybrid strategies that further improve tumor-selective delivery and activation. Beyond serving as delivery vehicles for immunomodulators, these PDNPs are utilized in synergy with chemotherapy, photothermal\/photodynamic therapy, and sonodynamic therapy to trigger immunogenic cell death. Furthermore, dendritic cell maturation and T-cell infiltration are promoted, thereby remodeling the immune microenvironment, particularly when administered in combination with immune checkpoint inhibitors. Finally, the key challenges and considerations for the clinical translation of tumor-activated PDNPs are highlighted, with the aim of guiding further research progress.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1968703","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:09:56Z","timestamp":1790248196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent advances in tumor-activated prodrug nanoparticles for cancer immunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Guanran","family":"Wang","sequence":"first","affiliation":[{"name":"China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Du","sequence":"additional","affiliation":[{"name":"China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikai","family":"Sun","sequence":"additional","affiliation":[{"name":"China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyuan","family":"Tong","sequence":"additional","affiliation":[{"name":"China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ren","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine, Tsinghua University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huicong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Key Laboratory and Engineering Laboratory of Lymphatic Surgery Jilin Province, China-Japan Union Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12151-6","article-title":"Globocan 2020 report on global cancer burden: Challenges and opportunities for surgical oncologists","volume":"29","author":"Deo","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01720-2","article-title":"Immunotherapies in rare cancers","volume":"22","author":"Vivekanandhan","year":"2023","journal-title":"Mol Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.831934","article-title":"Managing nutrition impact symptoms in cancer cachexia: A case series and mini review","volume":"9","author":"Khorasanchi","year":"2022","journal-title":"Front Nutr"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-006-0009-8","article-title":"Neurologic toxicities of cancer therapies","volume":"6","author":"Cavaliere","year":"2006","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: Harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: From enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02639-1","article-title":"Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity","volume":"130","author":"Akai","year":"2024","journal-title":"Br J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116162","article-title":"Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy","volume":"223","author":"Li","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41467-022-35710-7","article-title":"Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation","volume":"14","author":"Lin","year":"2023","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2018.05.001","article-title":"Defining and understanding adaptive resistance in cancer immunotherapy","volume":"39","author":"Kim","year":"2018","journal-title":"Trends Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cr.2016.155","article-title":"Immune targets and neoantigens for cancer immunotherapy and precision medicine","volume":"27","author":"Wang","year":"2017","journal-title":"Cell Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01679","article-title":"Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy","volume":"8","author":"Efremova","year":"2017","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.1038\/s41598-017-12414-3","article-title":"The in vivo antitumor effects of type I interferon against hepatocellular carcinoma: The suppression of tumor cell growth and angiogenesis","volume":"7","author":"Enomoto","year":"2017","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0902745106","article-title":"IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation","volume":"106","author":"Ben-Sasson","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"MMT49","DOI":"10.2217\/mmt-2020-0011","article-title":"An update on Gm-CSF and its potential role in melanoma management","volume":"7","author":"Dillman","year":"2020","journal-title":"Melanoma Manag"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.018","article-title":"Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8(+) T cells","volume":"48","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (Satri-Cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (Ct041-St-01): A randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: Phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06575-7","article-title":"The PTPN2\/PTPN1 inhibitor Abbv-Cls-484 unleashes potent anti-tumour immunity","volume":"622","author":"Baumgartner","year":"2023","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202511887","article-title":"Elemene augments the effects of anti-PD-1 immunotherapy on hepatocellular carcinoma by regulating the Mir-130a-5p\/Spp\/Mhc-I axis","volume":"13","author":"Wang","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35347","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: An empirical analysis","volume":"156","author":"Haslam","year":"2025","journal-title":"Int J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: A retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.fmre.2022.11.003","article-title":"Biodegradable nanoparticles-mediated targeted drug delivery achieves trans-spatial immunotherapy","volume":"4","author":"Wang","year":"2024","journal-title":"Fundam Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202508107","article-title":"Regulating tumor metabolic reprogramming with biomimetic co-delivery of simvastatin and kynureninase for immunotherapy","volume":"13","author":"Yin","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02448-0","article-title":"Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors","volume":"43","author":"Jiang","year":"2025","journal-title":"Nat Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/17435889.2024.2374230","article-title":"Advancements in nanomedicine delivery systems: Unraveling immune regulation strategies for tumor immunotherapy","volume":"19","author":"Zhang","year":"2024","journal-title":"Nanomedicine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat Rev Mater"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.05.024","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"7","author":"Joyce","year":"2005","journal-title":"Cancer Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.109.065706","article-title":"Of mice and humans: Are they the same?--Implications in cancer translational research","volume":"51","author":"De Jong","year":"2010","journal-title":"J Nucl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114363","article-title":"Enzyme-powered micellar nanoreactors enable tumor-specific, cascade-amplified prodrug activation for synergistic oxidation-chemo-immunotherapy","volume":"389","author":"Li","year":"2026","journal-title":"J Control Release"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202504414","article-title":"Cathepsin B-cleavable doxorubicin prodrug nanoparticles for eliciting cancer-specific immunogenic cell death and minimizing systemic toxicity","volume":"15","author":"Shim","year":"2026","journal-title":"Adv Healthc Mater"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.5c04498","article-title":"A tailor-made biaryl-stapled peptide nanoprodrug with esterase-triggered dual immunomodulation for amplified cancer therapy","volume":"25","author":"Jiang","year":"2025","journal-title":"Nano Lett"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.06.028","article-title":"Activatable PROTAC nanoassembly for photodynamic PTP1B proteolysis enhances glioblastoma immunotherapy","volume":"15","author":"Jang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c08856","article-title":"Carrier-free nanoprodrug mediating laser-activable chemotherapeutic immunomodulation against cancer","volume":"19","author":"Gao","year":"2025","journal-title":"ACS Nano"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2025.111335","article-title":"ROS-sensitive dihydroartemisinin prodrug amplify chemo-immunotherapy efficacy of doxorubicin by coordinating robust tumor cell immunogenic cell death and PD-L1 blockade","volume":"37","author":"Han","year":"2026","journal-title":"Chin Chem Lett"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.4c02287","article-title":"Ultrasound-activated PROTAC prodrugs overcome immunosuppression to actuate efficient deep-tissue sono-immunotherapy in orthotopic pancreatic tumor mouse models","volume":"24","author":"Liu","year":"2024","journal-title":"Nano Lett"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2025.101104","article-title":"A ROS\/photo dual-responsive prodrug unimolecular micelle for boosted cancer immunotherapy","volume":"20","author":"Huang","year":"2025","journal-title":"Asian J Pharm Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2025.111404","article-title":"A hypoxia-activated copper ion nanoexchanger for cancer immunotherapy by in situ precise production of immunogenic cell death inducer","volume":"37","author":"Zhang","year":"2026","journal-title":"Chin Chem Lett"},{"key":"B43","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"B44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-007-0281-3","article-title":"Hypoxia and cancer","volume":"85","author":"Brahimi-Horn","year":"2007","journal-title":"J Mol Med (Berl)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2023.11.001","article-title":"Hypoxia signaling and metastatic progression","volume":"97","author":"Schito","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.026","article-title":"100 years of the Warburg effect: A cancer metabolism endeavor","volume":"187","author":"Fendt","year":"2024","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg effect: How does it benefit cancer cells","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021993","article-title":"P22phox C242T single-nucleotide polymorphism inhibits inflammatory oxidative damage to endothelial cells and vessels","volume":"133","author":"Meijles","year":"2016","journal-title":"Circulation"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.05.003","article-title":"GSH-sensitive polymeric prodrug: Synthesis and loading with photosensitizers as nanoscale chemo-photodynamic anti-cancer nanomedicine","volume":"12","author":"Luo","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01634-6","article-title":"Harnessing the tumor microenvironment: Targeted cancer therapies through modulation of epithelial-mesenchymal transition","volume":"18","author":"Glaviano","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.3c14005","article-title":"Nanomedicine remodels tumor microenvironment for solid tumor immunotherapy","volume":"146","author":"Guo","year":"2024","journal-title":"J Am Chem Soc"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.06.008","article-title":"Photosensitive pro-drug nanoassemblies harboring a chemotherapeutic dormancy function potentiates cancer immunotherapy","volume":"13","author":"Cheng","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.10.015","article-title":"Tumor-dilated polymersome nanofactories for enhanced enzyme prodrug chemo-immunotherapy","volume":"339","author":"Japir","year":"2021","journal-title":"J Control Release"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202002380","article-title":"Tumor-activated size-enlargeable bioinspired lipoproteins access cancer cells in tumor to elicit anti-tumor immune responses","volume":"32","author":"Li","year":"2020","journal-title":"Adv Mater"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.106059","article-title":"Reversing adenosine-mediated immunosuppression in triple-negative breast cancer by synergistic chemo-immunotherapy via stimuli-responsive nanomedicines","volume":"123","author":"Cheng","year":"2026","journal-title":"Ebiomedicine"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202000214","article-title":"Prodrug-based versatile nanomedicine for enhancing cancer immunotherapy by increasing immunogenic cell death","volume":"16","author":"Bai","year":"2020","journal-title":"Small"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203353","article-title":"Stepwise size shrinkage cascade-activated supramolecular prodrug boosts antitumor immunity by eliciting pyroptosis","volume":"9","author":"Liang","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041241","article-title":"CD163+ monoclonal antibody modified polymer prodrug nanoparticles for targeting tumor-associated macrophages (TAMs) to enhance anti-tumor effects","volume":"15","author":"Yang","year":"2023","journal-title":"Pharmaceutics"},{"key":"B60","doi-asserted-by":"publisher","first-page":"113576","DOI":"10.1016\/j.jconrel.2025.02.072","article-title":"Breaking barriers: Nitric oxide-releasing nanocomplexes for collagen degradation and enhanced alphapd-L1 immunotherapy in deep tumor","volume":"381","author":"Lee","year":"2025","journal-title":"J Control Release"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123677","article-title":"ROS-responsive resiquimod prodrug nanoparticles for macrophage reprogramming and enhanced immune checkpoint inhibitor therapy in bladder cancer","volume":"326","author":"Geng","year":"2026","journal-title":"Biomaterials"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202307818","article-title":"An \"and\" logic-gated prodrug micelle locally stimulates antitumor immunity","volume":"36","author":"Chen","year":"2024","journal-title":"Adv Mater"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202305630","article-title":"PreciseRNA editing: Cascade self\u2010uncloaking dual\u2010prodrug nanoassemblies based on CRISPR\/Cas13a for pleiotropic immunotherapy of PD\u2010L1\u2010resistant colorectal cancer","volume":"33","author":"Zhang","year":"2023","journal-title":"Adv Funct Mater"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.4c05863","article-title":"Polymeric nanoparticles simultaneously delivering paclitaxel prodrug and combretastatin A4 with exceptionally high drug loading for cancer combination therapy","volume":"25","author":"Zhou","year":"2025","journal-title":"Nano Lett"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202312500","article-title":"Self\u2010carrier nanoparticles for delivery of paclitaxel and IDO inhibitor to boost antitumor chemo\u2010immunotherapy","volume":"34","author":"Li","year":"2024","journal-title":"Adv Funct Mater"},{"key":"B66","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/s12951-025-03559-9","article-title":"Curcumin-based polymer prodrug nanoplatform for high-efficiency immunotherapy by synergistically suppression of head and neck cancer cell stemness","volume":"23","author":"Shen","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113628","article-title":"Prodrug-designed nanocarrier co-delivering chemotherapeutic and vascular disrupting agents with exceptionally high drug loading capacity","volume":"382","author":"Zhou","year":"2025","journal-title":"J Control Release"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202400762","article-title":"Exosome\u2010inhibiting polymeric sonosensitizer for tumor\u2010specific sonodynamic immunotherapy","volume":"36","author":"Wu","year":"2024","journal-title":"Adv Mater"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2024.152174","article-title":"MMP-2\/GSH-responsive nanobomb for tumor chemo-immunotherapy with hierarchical delivery and TAMs re-education by regulating HBEGF-activated ERK\/MAPK signal pathway","volume":"491","author":"Zheng","year":"2024","journal-title":"Chem Eng J"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201907210","article-title":"Engineering stimuli-activatable boolean logic prodrug nanoparticles for combination cancer immunotherapy","volume":"32","author":"Hou","year":"2020","journal-title":"Adv Mater"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s12274-022-4598-6","article-title":"A prodrug nanoplatform via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy","volume":"15","author":"Syeda","year":"2022","journal-title":"Nano Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.0c01928","article-title":"Potent and prolonged innate immune activation by enzyme-responsive imidazoquinoline TLR7\/8 agonist prodrug vesicles","volume":"142","author":"Wang","year":"2020","journal-title":"J Am Chem Soc"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.123032","article-title":"PPS-TLR7\/8 agonist nanoparticles equip robust anticancer immunity by selectively prolonged activation of dendritic cells","volume":"316","author":"Zhang","year":"2025","journal-title":"Biomaterials"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.02.015","article-title":"Hypoxia inducible factor-1alpha drives cancer resistance to cuproptosis","volume":"43","author":"Yang","year":"2025","journal-title":"Cancer Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00781-9","article-title":"Tumour hypoxia in driving genomic instability and tumour evolution","volume":"25","author":"Suvac","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s0305-7372(03)00003-3","article-title":"Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies","volume":"29","author":"Shannon","year":"2003","journal-title":"Cancer Treat Rev"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605311","article-title":"Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells","volume":"101","author":"Roberts","year":"2009","journal-title":"Br J Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03894-x","article-title":"Hypoxia-activated paclitaxel prodrugs enable PD-L1 degradation to potentiate cancer chemo-immunotherapy","volume":"24","author":"Zhou","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.01.008","article-title":"Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation","volume":"379","author":"Zhang","year":"2025","journal-title":"J Control Release"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcis.2025.138774","article-title":"A hypoxia-responsive nanomedicine for cancer immunotherapy through ligand competition-induced dual-prodrug activation","volume":"701","author":"Li","year":"2026","journal-title":"J Colloid Interface Sci"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwae038","article-title":"Introducing urea into tirapazamine derivatives to enhance anticancer therapy","volume":"11","author":"Xu","year":"2024","journal-title":"Natl Sci Rev"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202505833","article-title":"Hypoxia-activated imidazoquinoline prodrug nanoparticles potentiate radiofrequency ablation-mediated antitumor immunity against hepatocellular carcinoma","volume":"21","author":"Ji","year":"2025","journal-title":"Small"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113789","article-title":"Hypoxia-responsive albumin nanoparticles co-delivering banoxantrone and STING agonist enhance immunotherapy of high-intensity focused ultrasound","volume":"383","author":"Huang","year":"2025","journal-title":"J Control Release"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202312493","article-title":"Tumor microenvironment remodeling-mediated sequential drug delivery potentiates treatment efficacy","volume":"36","author":"Xu","year":"2024","journal-title":"Adv Mater"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202207733","article-title":"Azide-masked resiquimod activated by hypoxia for selective tumor therapy","volume":"35","author":"Sun","year":"2023","journal-title":"Adv Mater"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-023-00617-2","article-title":"Responsive biomaterials: Optimizing control of cancer immunotherapy","volume":"9","author":"Xue","year":"2023","journal-title":"Nat Rev Mater"},{"key":"B87","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/php.13570","article-title":"Photocleavage-based photoresponsive drug delivery","volume":"98","author":"Liu","year":"2022","journal-title":"Photochem Photobiol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.05.016","article-title":"Light-responsive nanomedicine for cancer immunotherapy","volume":"13","author":"Kang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2022.06.041","article-title":"A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy","volume":"149","author":"Ding","year":"2022","journal-title":"Acta Biomater"},{"key":"B90","doi-asserted-by":"publisher","first-page":"8112","DOI":"10.1038\/s41467-023-43805-y","article-title":"Near-infrared light-triggered prodrug photolysis by one-step energy transfer","volume":"14","author":"Long","year":"2023","journal-title":"Nat Commun"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41557-020-00624-8","article-title":"Mechanochemical bond scission for the activation of drugs","volume":"13","author":"Huo","year":"2021","journal-title":"Nat Chem"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1039\/d0sc06054b","article-title":"Mechanochemical activation of disulfide-based multifunctional polymers for theranostic drug release","volume":"12","author":"Shi","year":"2020","journal-title":"Chem Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c03416","article-title":"Visible-light-triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy","volume":"15","author":"Choi","year":"2021","journal-title":"ACS Nano"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202425309","article-title":"Near\u2010infrared light\u2010responsive immunomodulator prodrugs rejuvenating immune microenvironment for \u201ccold\u201d tumor photoimmunotherapy","volume":"64","author":"Shen","year":"2025","journal-title":"Angew Chem Int Ed"},{"key":"B95","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41467-024-55529-8","article-title":"Hypoxia-tolerant polymeric photosensitizer prodrug for cancer photo-immunotherapy","volume":"16","author":"Yu","year":"2025","journal-title":"Nat Commun"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202405475","article-title":"Light\u2010triggered PROTAC nanoassemblies for photodynamic IDO proteolysis in cancer immunotherapy","volume":"36","author":"Choi","year":"2024","journal-title":"Adv Mater"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202419395","article-title":"Hierarchical targeting nanoplatform for NIR\u2010II photoacoustic imaging and photo\u2010activated synergistic immunotherapy of glioblastoma","volume":"35","author":"Zhang","year":"2025","journal-title":"Adv Funct Mater"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202512104","article-title":"A sono-responsive nanoplatform integrating STING activation and CXCR4 blockade for synergistic immunotherapy of glioblastoma","volume":"38","author":"Kang","year":"2026","journal-title":"Adv Mater"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c10301","article-title":"Ultrasound-mediated piezocatalysis triggers NO release to augment targeted immunotherapy of pancreatic cancer","volume":"19","author":"Song","year":"2025","journal-title":"ACS Nano"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1039\/d5bm00755k","article-title":"Ultrasound-responsive azide nano-prodrugs enable spatiotemporal activation of TLR7\/8 agonists for tumor therapy","volume":"13","author":"Luo","year":"2025","journal-title":"Biomater Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202425565","article-title":"Ultrasound\u2010triggered cascade delivery via poly\u2010oxaliplatin nanoparticles for immunotherapy","volume":"35","author":"Shen","year":"2025","journal-title":"Adv Funct Mater"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202501871","article-title":"A self-adaptive rhodium(I) complex-based nanoplatform with type II immunogenic cell death for near-infrared phosphorescence imaging and cancer immunotherapy","volume":"14","author":"Xiang","year":"2025","journal-title":"Adv Healthc Mater"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2026.176643","article-title":"A full active pharmaceutical ingredients-based nanoplatform potentiates tumor immunotherapy via multidimensional cGAS-STING pathway activation","volume":"537","author":"Wang","year":"2026","journal-title":"Chem Eng J"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1039\/c7md00109f","article-title":"Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry","volume":"8","author":"Coletti","year":"2017","journal-title":"Medchemcomm"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24676","article-title":"A phase-1\/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer","volume":"9","author":"Soliman","year":"2018","journal-title":"Oncotarget"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.3020","article-title":"Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (Ido) inhibitor indoximod plus gemcitabine\/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis","volume":"34","author":"Bahary","year":"2016","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-0309","article-title":"Quantitative spatial profiling of PD-1\/PD-L1 interaction and HLA-DR\/IDO-1 predicts improved outcomes of anti\u2013PD-1 therapies in metastatic melanoma","volume":"24","author":"Johnson","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.02094.x","article-title":"Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer","volume":"102","author":"Huang","year":"2011","journal-title":"Cancer Sci"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (Echo-301\/Keynote-252): A phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad174","article-title":"Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial","volume":"26","author":"Johnson","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B111","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1182\/blood-2018-99-117433","article-title":"Indoximod combined with standard induction chemotherapy is well tolerated and induces a high rate of complete remission with MRD-negativity in patients with newly diagnosed AML: Results from a phase 1 trial","volume":"132","author":"Emadi","year":"2018","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.003","article-title":"The STING pathway and the T cell-inflamed tumor microenvironment","volume":"36","author":"Woo","year":"2015","journal-title":"Trends Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011572","article-title":"Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide sting agonist, for patients with advanced solid tumor Malignancies","volume":"13","author":"Jacoby","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-24-3630","article-title":"Phase I and II clinical studies of the STING agonist ulevostinag with and without pembrolizumab in participants with advanced or metastatic solid tumors or lymphomas","volume":"31","author":"Harrington","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.079","article-title":"Clinical efficacy, safety, and PK\/PD from the first in human study of BM201, a TLR7\/8 agonist","volume":"35","author":"Li","year":"2024","journal-title":"Ann Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002953","article-title":"Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy","volume":"9","author":"Alvarez","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B118","doi-asserted-by":"publisher","first-page":"A601","DOI":"10.1136\/jitc-2021-SITC2021.572","article-title":"Combination therapy of exoSTING, exoIL-12 activates systemic anti-tumor immunity","volume":"9","author":"Kirwin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101941","article-title":"Rhodium-based metallodrugs for biological applications: Current status and future perspectives","volume":"33","author":"Xiang","year":"2025","journal-title":"Mater Today Bio"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-026-04022-z","article-title":"Glutathione responsive iNOs inhibiting polymeric prodrug for targeted inhibition of angiogenesis","volume":"24","author":"Alimoradi","year":"2026","journal-title":"J Nanobiotechnol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c02897","article-title":"A ROS-responsive dimeric prodrug nanoassembly for amplified epigenetic therapy of lymphoma","volume":"69","author":"Li","year":"2026","journal-title":"J Med Chem"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202529287","article-title":"Hypoxia\u2010responsive nanosystem for synergistic cancer therapy: Enhancing ferroptosis via a novel GPX4 inhibitor and facilitating precise photodynamic therapy","volume":"36","author":"Wang","year":"2026","journal-title":"Adv Funct Mater"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2022.02.002","article-title":"Impact of the amount of PEG on prodrug nanoassemblies for efficient cancer therapy","volume":"17","author":"Li","year":"2022","journal-title":"Asian J Pharm Sci"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-025-00648-6","article-title":"Dual character of surface engineering on SN38 prodrug nano-assemblies: Divergent effects on in vitro and in vivo behavior","volume":"12","author":"Li","year":"2025","journal-title":"Mil Med Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.10.010","article-title":"Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles","volume":"307","author":"OwensIII","year":"2006","journal-title":"Int J Pharm"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1021\/ja2084338","article-title":"Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake","volume":"134","author":"Walkey","year":"2012","journal-title":"J Am Chem Soc"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2018.01.011","article-title":"Influence of ligands property and particle size of gold nanoparticles on the protein adsorption and corresponding targeting ability","volume":"538","author":"Xiao","year":"2018","journal-title":"Int J Pharm"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c03978","article-title":"Multilayered nanoarchitectonics of poly(ethylene glycol) nanoparticles with tunable stiffness modulate bio\u2013nano interactions and targeted drug delivery","volume":"19","author":"Li","year":"2025","journal-title":"ACS Nano"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c08922","article-title":"Glycopolymeric nanoparticles enrich less immunogenic protein coronas, reduce mononuclear phagocyte clearance, and improve tumor delivery compared to pegylated nanoparticles","volume":"18","author":"Hulugalla","year":"2024","journal-title":"ACS Nano"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-008-9697-x","article-title":"Intravascular delivery of particulate systems: Does geometry really matter","volume":"26","author":"Decuzzi","year":"2008","journal-title":"Pharm Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-019-0567-y","article-title":"Smart cancer nanomedicine","volume":"14","author":"Van der Meel","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202500748","article-title":"Protein\u2010nonfouling and cell\u2010binding polysulfobetaine inducing fast transcytosis for tumor\u2010active drug delivery","volume":"37","author":"Li","year":"2025","journal-title":"Adv Mater"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54265-3","article-title":"Rational strategies for improving the efficiency of design and discovery of nanomedicines","volume":"15","author":"Shan","year":"2024","journal-title":"Nat Commun"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202415902","article-title":"Machine learning-driven prediction, preparation, and evaluation of functional nanomedicines via drug\u2013drug self-assembly","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B136","doi-asserted-by":"publisher","first-page":"10804","DOI":"10.1038\/s41467-024-55072-6","article-title":"Artificial intelligence-driven rational design of ionizable lipids for mRNA delivery","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"B137","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1038\/s41467-024-50619-z","article-title":"AGILE platform: A deep learning powered approach to accelerate LNP development for mRNA delivery","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01975-4","article-title":"Designing lipid nanoparticles using a transformer-based neural network","volume":"20","author":"Chan","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41524-021-00614-5","article-title":"Evolutionary computational platform for the automatic discovery of nanocarriers for cancer treatment","volume":"7","author":"Stillman","year":"2021","journal-title":"NPJ Comput Mater"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00880","article-title":"A comprehensive study on nanoparticle drug delivery to the brain: Application of machine learning techniques","volume":"21","author":"Yousfan","year":"2023","journal-title":"Mol Pharmaceutics"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.compchemeng.2025.109081","article-title":"Machine learning enabled multiscale model for nanoparticle margination and physiology based pharmacokinetics","volume":"198","author":"Kulkarni","year":"2025","journal-title":"Comput Chem Eng"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2019.114765","article-title":"Endocytosis mechanism in physiologically-based pharmacokinetic modeling of nanoparticles","volume":"384","author":"Deng","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jconrel.2023.07.040","article-title":"An artificial intelligence-assisted physiologically-based pharmacokinetic model to predict nanoparticle delivery to tumors in mice","volume":"361","author":"Chou","year":"2023","journal-title":"J Controlled Release"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-024-01673-7","article-title":"A large-scale machine learning analysis of inorganic nanoparticles in preclinical cancer research","volume":"19","author":"Mendes","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202510239","article-title":"Artificial intelligence-driven nanoarchitectonics for smart targeted drug delivery","volume":"37","author":"Bae","year":"2025","journal-title":"Adv Mater"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00847-2","article-title":"Advancing engineering design strategies for targeted cancer nanomedicine","volume":"25","author":"Gomerdinger","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s44222-023-00138-1","article-title":"Controlling the biodistribution and clearance of nanomedicines","volume":"2","author":"Cabral","year":"2024","journal-title":"Nat Rev Bioeng"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: Modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.08.010","article-title":"Patient-derived organoids in precision cancer medicine","volume":"5","author":"Tong","year":"2024","journal-title":"Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1968703\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:09:57Z","timestamp":1790248197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1968703\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":149,"alternative-id":["10.3389\/fimmu.2026.1968703"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1968703","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1968703"}}